TCTR20230407003终止2 期
(Effect of dose-escalation protocol for capecitabine on dose in 4th cycle of chemotherapy (Es- Cape 01))
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •Patients suffered from metastatic breast cancer, colorectal cancer, gastroesophageal adenocarcinoma, or gastric cancer indicated for capecitabine combination regimen and justified to use capecitabine attended to Medical Oncology outpatient department Srinagarind hospital from 20th July 2022 to 31st October 2022. Due to slow accrual, the inclusion period was amended to add period from 17th November 2022 to 31st December 2022. The Eastern Cooperative Oncology Group performance status must be 0 or 1 and adequate organ function was required. Women of childbearing age and potential must have negative pregnancy test result and have adequate contraception.
排除标准
- •Patients with incomplete recovery from surgery (if done), patient with resectable metastasis colorectal cancer, history of other malignancies within 5 years, any concomitant use of other investigational agents during the study treatment period, history of capecitabine allergy, pregnancy, breast-feeding, concomitant use of vitamin K antagonist or uncontrolled medical conditions judged by investigators
研究者
相似试验
招募中
1 期
A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid TumorsRelapsed Solid Tumor / Refractory Solid TumorJPRN-jRCT2031210562Masaki Takeshi60
进行中（未招募）
1 期
A Phase 1b Study of Abemaciclib Plus Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Solid TumorsPediatric and Young Adult Patients Relapsed/Refractory Solid TumorsMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10039022Term: RhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10031291Term: OsteosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10014967Term: EpendymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002931-27-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER60
招募中
2 期
A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide.systemic sclerosisAutoimmune disorderACTRN12617000216314St Vincent's Hospital Sydney15
已完成
不适用
Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaireOveractive BladderJPRN-UMIN000004894Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan500
进行中（未招募）
1 期
A mouthwash medicine for the reduction or prevention of mouth ulceration caused by radiotherapy for head and neck cancerISRCTN87831050VasoDynamics Ltd32